Compare RVLV & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | AVLN |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2026 |
| Metric | RVLV | AVLN |
|---|---|---|
| Price | $24.02 | $27.96 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $29.73 | N/A |
| AVG Volume (30 Days) | ★ 846.5K | 520.1K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.64 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $115.65 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $27.33 |
| 52 Week High | $31.68 | $33.32 |
| Indicator | RVLV | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 32.04 |
| Support Level | $21.61 | $27.37 |
| Resistance Level | $24.06 | $29.48 |
| Average True Range (ATR) | 0.98 | 2.48 |
| MACD | 0.10 | -0.30 |
| Stochastic Oscillator | 99.70 | 14.40 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.